{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:54:28Z","timestamp":1789239268182,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In comparison with TNF\u2010\u03b1 inhibitors, anti\u2010IL\u201017A agents are considered to have a lower risk of active tuberculosis (TB) or latent TB infection (LTBI) reactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we aimed to evaluate the TB infection status and serial QuantiFERON\u2010TB\u2010Gold in tube test (QFT) results of psoriasis patients using IL\u201017 inhibitors (secukinumab [SEC] and ixekizumab [IXE]) in a real\u2010world setting from a tuberculosis\u2010endemic country. Patients who used an anti\u2010IL\u201017 agent for at least 3\u2009months in our follow\u2010up were included in the study. Patients' clinical and demographic features, baseline QFT results and latest QFT results (if any), and TB infection status were noted from the past medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 717 patients, of whom 333 (46.4%) were female, were included in the study. The cumulative exposure time to an anti\u2010IL\u201017 agent was 14,147 patient\u2010months, 9743 patient\u2010months for SEC and 4404 patient\u2010months for IXE. Also, 459 (SEC\u2009=\u2009305\/IXE\u2009=\u2009154) patients used an anti\u2010IL\u201017 agent for \u2265\u200912\u2009months. Of these, 125 had positive baseline QFT results. In all, 334 had negative baseline QFT results. The latest QFT result of 309 was also negative (persistent seronegative group). During follow\u2010up, the QFT results of 10 patients changed from negative to positive (positive seroconversion group). Seven of them were using SEC and three were using IXE, respectively. No case of active TB infection was detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our study, the positive seroconversion rate of 10\/334 seems high, but this did not translate to active disease. However, closer monitoring may be required, especially in patients with advanced age, the presence of PsA, long disease duration and long anti\u2010IL\u201017 treatment duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajd.14340","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T05:14:58Z","timestamp":1719810898000},"page":"567-575","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of serial\n                    <scp>QuantiFERON<\/scp>\n                    \u2010\n                    <scp>TB<\/scp>\n                    Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti\u2010\n                    <scp>IL<\/scp>\n                    \u201017 treatment (secukinumab and ixekizumab): Real\u2010world data from a tuberculosis\u2010endemic country"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-0492","authenticated-orcid":false,"given":"Ece","family":"Erba\u011fc\u0131","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology U\u015fak University Training and Research Hospital  U\u015fak Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0633-1770","authenticated-orcid":false,"given":"Sema","family":"Ko\u00e7 Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology U\u015fak University Training and Research Hospital  U\u015fak Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Asl\u0131","family":"Hapa","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology \u0130zmir Demokrasi University Buca Seyfi Demirsoy Training and Research Hospital  \u0130zmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102016\u2010012567"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075\u2010019\u20101882\u20102"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.012"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15723"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225112"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000745\u20107"},{"key":"e_1_2_9_10_1","volume-title":"Tuberculosis profile","author":"WHO Global Tuberculosis Report","year":"2023"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200402\u2010179OC"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16926"},{"key":"e_1_2_9_15_1","volume-title":"T\u00fcrkiye Psoriasis Tedavi K\u0131lavuzu","author":"Ad\u0131\u015fen E","year":"2021"},{"key":"e_1_2_9_16_1","volume-title":"T\u00fcrkiye Cumhuriyeti Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 T\u00fcberk\u00fcloz Tan\u0131 ve Tedavi Rehberi","author":"Er AG","year":"2019"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416651605"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00498"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.10.004"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16866"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16254"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15217"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14699"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14512"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501989"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201000998\u2010w"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3909"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2022.10.032"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010024\u201000845\u20104"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.14340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T08:11:24Z","timestamp":1735891884000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.14340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/ajd.14340"],"URL":"https:\/\/doi.org\/10.1111\/ajd.14340","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3645910\/v1","asserted-by":"object"}]},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}